Nanomedicine strategies to target tumor-associated macrophages

International Journal of Molecular Sciences

Volumn 18, Issue 5, 2017, Pages

  Binnemars Postma, Karin ^a   Storm, Gert ^a,b   Prakash, Jai ^a  

^a UNIVERSITY OF TWENTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Active targeting; Cancer; Macrophages; Nanoparticles; Passive targeting; Tumor associated macrophages

Indexed keywords

CARBON NANOTUBE; CARLUMAB; CD11B ANTIGEN; CD68 ANTIGEN; CHEMOKINE RECEPTOR CCR4; FOLATE RECEPTOR; GALAPTIN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; LEGUMAIN; LIPOSOME; MANNOSE RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NANOPARTICLE; RISEDRONIC ACID; SILICA NANOPARTICLE; TUMOR NECROSIS FACTOR; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; VASCULOTROPIN;

ANGIOGENESIS; CELL INFILTRATION; DNA DAMAGE; DNA REPAIR; HUMAN; INFLAMMATION; METASTASIS; NANOMEDICINE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHENOTYPE; POLARIZATION; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR INVASION; WOUND HEALING; ANIMAL; CHEMISTRY; CLASSIFICATION; IMMUNOLOGY; MACROPHAGE; MACROPHAGE ACTIVATION; NEOPLASM; PROCEDURES;

ANIMALS; HUMANS; MACROPHAGE ACTIVATION; MACROPHAGES; NANOMEDICINE; NANOPARTICLES; NEOPLASMS;

EID: 85018408498     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18050979     Document Type: Review

References (191)

1. Balkwill, F.; Mantovani, A. Inflammation and cancer: Back to Virchow? Lancet 2001, 357, 539–545. [CrossRef]
2. Brigati, C.; Noonan, D.M.; Albini, A.; Benelli, R. Tumors and inflammatory infiltrates: Friends or foes? Clin. Exp. Metastasis 2002, 19, 247–258. [CrossRef] [PubMed]
3. Liotta, L.A.; Kohn, E.C. The microenvironment of the tumour-host interface. Nature 2001, 411, 375–379. [CrossRef] [PubMed]
4. Dvorak, H.F. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986, 315, 1650–1659. [PubMed]
5. Hagerling, C.; Casbon, A.J.; Werb, Z. Balancing the innate immune system in tumor development. Trends Cell Biol. 2015, 25, 214–220. [CrossRef] [PubMed]
6. Elinav, E.; Nowarski, R.; Thaiss, C.A.; Hu, B.; Jin, C.; Flavell, R.A. Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer 2013, 13, 759–771. [CrossRef] [PubMed]
7. Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature 2008, 454, 436–444. [CrossRef] [PubMed]
8. Koehne, C.H.; Dubois, R.N. COX-2 inhibition and colorectal cancer. Semin. Oncol. 2004, 31, S12–S21. [CrossRef]
9. Flossmann, E.; Rothwell, P.M. Effect of aspirin on long-term risk of colorectal cancer: Consistent evidence from randomised and observational studies. Lancet 2007, 369, 1603–1613. [CrossRef]
10. Sica, A.; Allavena, P.; Mantovani, A. Cancer related inflammation: The macrophage connection. Cancer Lett. 2008, 267, 204–215. [CrossRef] [PubMed]
11. Pollard, J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004, 4, 71–78. [CrossRef] [PubMed]
12. Allavena, P.; Mantovani, A. Immunology in the clinic review series; focus on cancer: Tumour-associated macrophages: Undisputed stars of the inflammatory tumour microenvironment. Clin. Exp. Immunol. 2012, 167, 195–205. [CrossRef] [PubMed]
13. Sica, A.; Schioppa, T.; Mantovani, A.; Allavena, P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. Eur. J. Cancer 2006, 42, 717–727. [CrossRef] [PubMed]
14. Shoenfeld, Y.; Tal, A.; Berliner, S.; Pinkhas, J. Leukocytosis in non hematological malignancies—A possible tumor-associated marker. J. Cancer Res. Clin. Oncol. 1986, 111, 54–58. [CrossRef] [PubMed]
15. Fridlender, Z.G.; Albelda, S.M. Tumor-associated neutrophils: Friend or foe? Carcinogenesis 2012, 33, 949–955. [CrossRef] [PubMed]
16. Pillay, J.; Tak, T.; Kamp, V. M.; Koenderman, L. Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: Similarities and differences. Cell. Mol. Life Sci. 2013, 70, 3813–3827. [CrossRef] [PubMed]
17. Dumitru, C.A.; Lang, S.; Brandau, S. Modulation of neutrophil granulocytes in the tumor microenvironment: Mechanisms and consequences for tumor progression. Semin. Cancer Biol. 2013, 23, 141–148. [CrossRef] [PubMed]
18. Brandau, S.; Moses, K.; Lang, S. The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: Cousins, siblings or twins? Semin. Cancer Biol. 2013, 23, 171–182. [CrossRef] [PubMed]
19. Okabe, Y.; Medzhitov, R. Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell 2014, 157, 832–844. [CrossRef] [PubMed]
20. Locati, M.; Mantovani, A.; Sica, A. Macrophage activation and polarization as an adaptive component of innate immunity. Adv. Immunol. 2013, 120, 163–184. [PubMed]
21. Epelman, S.; Lavine, K.J.; Randolph, G.J. Origin and functions of tissue macrophages. Immunity 2014, 41, 21–35. [CrossRef] [PubMed]
22. Sica, A.; Erreni, M.; Allavena, P.; Porta, C. Macrophage polarization in pathology. Cell. Mol. Life Sci. 2015, 72, 4111–4126. [CrossRef] [PubMed]
23. Martinez, F.O.; Gordon, S. The M1 and M2 paradigm of macrophage activation: Time for reassessment. F1000Prime Rep. 2014, 6, 13. [CrossRef] [PubMed]
24. Nau, G.J.; Richmond, J.F.; Schlesinger, A.; Jennings, E.G.; Lander, E.S.; Young, R.A. Human macrophage activation programs induced by bacterial pathogens. Proc. Natl. Acad. Sci. USA 2002, 99, 1503–1508. [CrossRef] [PubMed]
25. Mantovani, A.; Sica, A.; Sozzani, S.; Allavena, P.; Vecchi, A.; Locati, M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25, 677–686. [CrossRef] [PubMed]
26. Heusinkveld, M.; van der Burg, S.H. Identification and manipulation of tumor associated macrophages in human cancers. J. Transl. Med. 2011, 9, 216. [CrossRef] [PubMed]
27. Hao, N.B.; Lu, M.H.; Fan, Y.H.; Cao, Y.L.; Zhang, Z.R.; Yang, S.M. Macrophages in tumor microenvironments and the progression of tumors. Clin. Dev. Immunol. 2012, 2012, 948098. [CrossRef] [PubMed]
28. Biswas, S.K.; Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat. Immunol. 2010, 11, 889–896. [CrossRef] [PubMed]
29. Mills, C.D. M1 and M2 macrophages: Oracles of health and disease. Crit. Rev. Immunol. 2012, 32, 463–488. [CrossRef] [PubMed]
30. Mills, C.D.; Shearer, J.; Evans, R.; Caldwell, M.D. Macrophage arginine metabolism and the inhibition or stimulation of cancer. J. Immunol. 1992, 149, 2709–2714. [PubMed]
31. Heusinkveld, M.; de Vos van Steenwijk, P.J.; Goedemans, R.; Ramwadhdoebe, T.H.; Gorter, A.; Welters, M.J.; van Hall, T.; van der Burg, S.H. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J. Immunol. 2011, 187, 1157–1165. [CrossRef] [PubMed]
32. Fujiwara, Y.; Komohara, Y.; Kudo, R.; Tsurushima, K.; Ohnishi, K.; Ikeda, T.; Takeya, M. Oleanolic acid inhibits macrophage differentiation into the M2 phenotype and glioblastoma cell proliferation by suppressing the activation of STAT3. Oncol. Rep. 2011, 26, 1533–1537. [PubMed]
33. Oishi, K.; Sakaguchi, T.; Baba, S.; Suzuki, S.; Konno, H. Macrophage density and macrophage colony-stimulating factor expression predict the postoperative prognosis in patients with intrahepatic cholangiocarcinoma. Surg. Today 2015, 45, 715–722. [CrossRef] [PubMed]
34. Ding, T.; Xu, J.; Wang, F.; Shi, M.; Zhang, Y.; Li, S.P.; Zheng, L. High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum. Pathol. 2009, 40, 381–389. [CrossRef] [PubMed]
35. Mantovani, A.; Allavena, P.; Sica, A. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: Role in tumour progression. Eur. J. Cancer 2004, 40, 1660–1667. [CrossRef] [PubMed]
36. Colegio, O.R.; Chu, N.Q.; Szabo, A.L.; Chu, T.; Rhebergen, A.M.; Jairam, V.; Cyrus, N.; Brokowski, C.E.; Eisenbarth, S.C.; Phillips, G.M. et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 2014, 513, 559–563. [CrossRef] [PubMed]
37. Sica, A.; Saccani, A.; Bottazzi, B.; Polentarutti, N.; Vecchi, A.; van Damme, J.; Mantovani, A. Autocrine production of IL-10 mediates defective IL-12 production and NF-κB activation in tumor-associated macrophages. J. Immunol. 2000, 164, 762–767. [CrossRef] [PubMed]
38. Rebe, C.; Vegran, F.; Berger, H.; Ghiringhelli, F. STAT3 activation: A key factor in tumor immunoescape. JAKSTAT 2013, 2, e23010. [PubMed]
39. Zhang, Y.; Choksi, S.; Chen, K.; Pobezinskaya, Y.; Linnoila, I.; Liu, Z.G. ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages. Cell Res. 2013, 23, 898–914. [CrossRef] [PubMed]
40. Yuan, Z.Y.; Luo, R.Z.; Peng, R.J.; Wang, S.S.; Xue, C. High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis. Onco Targets Ther. 2014, 7, 1475–1480. [CrossRef] [PubMed]
41. Kubler, K.; Ayub, T.H.; Weber, S.K.; Zivanovic, O.; Abramian, A.; Keyver-Paik, M.D.; Mallmann, M.R.; Kaiser, C.; Serce, N.B.; Kuhn, W.; et al. Prognostic significance of tumor-associated macrophages in endometrial adenocarcinoma. Gynecol. Oncol. 2014, 135, 176–183. [CrossRef] [PubMed]
42. Biswas, S.K.; Allavena, P.; Mantovani, A. Tumor-associated macrophages: Functional diversity, clinical significance, and open questions. Semin. Immunopathol. 2013, 35, 585–600. [CrossRef] [PubMed]
43. Qian, B.Z.; Pollard, J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141, 39–51. [CrossRef] [PubMed]
44. Lin, E.Y.; Nguyen, A.V.; Russell, R.G.; Pollard, J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 2001, 193, 727–740. [CrossRef] [PubMed]
45. Wyckoff, J.; Wang, W.; Lin, E.Y.; Wang, Y.; Pixley, F.; Stanley, E.R.; Graf, T.; Pollard, J.W.; Segall, J.; Condeelis, J. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004, 64, 7022–7029. [CrossRef] [PubMed]
46. Wyckoff, J.B.; Wang, Y.; Lin, E.Y.; Li, J.F.; Goswami, S.; Stanley, E.R.; Segall, J.E.; Pollard, J.W.; Condeelis, J. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007, 67, 2649–2656. [CrossRef] [PubMed]
47. Hagemann, T.; Robinson, S.C.; Schulz, M.; Trumper, L.; Balkwill, F.R.; Binder, C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-α dependent up-regulation of matrix metalloproteases. Carcinogenesis 2004, 25, 1543–1549. [CrossRef] [PubMed]
48. Ingman, W.V.; Wyckoff, J.; Gouon-Evans, V.; Condeelis, J.; Pollard, J.W. Macrophages promote collagen fibrillogenesis around terminal end buds of the developing mammary gland. Dev. Dyn. 2006, 235, 3222–3229. [CrossRef] [PubMed]
49. Condeelis, J.; Segall, J.E. Intravital imaging of cell movement in tumours. Nat. Rev. Cancer 2003, 3, 921–930. [CrossRef] [PubMed]
50. Du, R.; Lu, K.V.; Petritsch, C.; Liu, P.; Ganss, R.; Passegue, E.; Song, H.; Vandenberg, S.; Johnson, R.S.; Werb, Z.; et al. HIF α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13, 206–220. [CrossRef] [PubMed]
51. Casazza, A.; Laoui, D.; Wenes, M.; Rizzolio, S.; Bassani, N.; Mambretti, M.; Deschoemaeker, S.; van Ginderachter, J.A.; Tamag, L.; Mazzone, M. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 2013, 24, 695–709. [CrossRef] [PubMed]
52. Guruvayoorappan, C. Tumor versus tumor-associated macrophages: How hot is the link? Integr. Cancer Ther. 2008, 7, 90–95. [CrossRef] [PubMed]
53. Mantovani, A.; Savino, B.; Locati, M.; Zammataro, L.; Allavena, P.; Bonecchi, R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010, 21, 27–39. [CrossRef] [PubMed]
54. Lazennec, G.; Richmond, A. Chemokines and chemokine receptors: New insights into cancer-related inflammation. Trends Mol. Med. 2010, 16, 133–144. [CrossRef] [PubMed]
55. Gazzaniga, S.; Bravo, A.I.; Guglielmotti, A.; van Rooijen, N.; Maschi, F.; Vecchi, A.; Mantovani, A.; Mordoh, J.; Wainstok, R. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J. Investig. Dermatol. 2007, 127, 2031–2041. [CrossRef] [PubMed]
56. Pienta, K.J.; Machiels, J.P.; Schrijvers, D.; Alekseev, B.; Shkolnik, M.; Crabb, S.J.; Li, S.; Seetharam, S.; Puchalski, T.A.; Takimoto, C.; et al. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Investig. New Drugs 2013, 31, 760–768. [CrossRef] [PubMed]
57. Sandhu, S.K.; Papadopoulos, K.; Fong, P.C.; Patnaik, A.; Messiou, C.; Olmos, D.; Wang, G.; Tromp, B.J.; Puchalski, T.A.; Balkwill, F. et al. A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother. Pharmacol. 2013, 71, 1041–1050. [CrossRef] [PubMed]
58. ClinicalTrials.gov, N.L.o.H. MLN1202 in Treating Patients with Bone Metastases. Available online: https://clinicaltrials.gov/ct2/show/NCT01015560 (accessed on 7 March 2017).
59. Ahn, G.O.; Tseng, D.; Liao, C.H.; Dorie, M.J.; Czechowicz, A.; Brown, J.M. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc. Natl. Acad. Sci. USA 2010, 107, 8363–8368. [CrossRef] [PubMed]
60. Arnaout, M.A. Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood 1990, 75, 1037–1050. [PubMed]
61. Prada, C.E.; Jousma, E.; Rizvi, T.A.; Wu, J.; Dunn, R.S.; Mayes, D.A.; Cancelas, J.A.; Dombi, E.; Kim, M.O.; West, B.L.; et al. Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neuropathol. 2013, 125, 159–168. [CrossRef] [PubMed]
62. Strachan, D.C.; Ruffell, B.; Oei, Y.; Bissell, M.J.; Coussens, L.M.; Pryer, N.; Daniel, D. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 T cells. Oncoimmunology 2013, 2, e26968. [CrossRef] [PubMed]
63. Weizman, N.; Krelin, Y.; Shabtay-Orbach, A.; Amit, M.; Binenbaum, Y.; Wong, R.J.; Gil, Z. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. Oncogene 2014, 33, 3812–3819. [CrossRef] [PubMed]
64. Pyonteck, S.M.; Akkari, L.; Schuhmacher, A.J.; Bowman, R.L.; Sevenich, L.; Quail, D.F.; Olson, O.C.; Quick, M.L.; Huse, J.T.; Teijeiro, V.; et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 2013, 19, 1264–1272. [CrossRef] [PubMed]
65. Sluijter, M.; van der Sluis, T.C.; van der Velden, P.A.; Versluis, M.; West, B.L.; van der Burg, S.H.; van Hall, T. Inhibition of CSF-1R supports T-cell mediated melanoma therapy. PLoS ONE 2014, 9, e104230. [CrossRef] [PubMed]
66. Kim, T.S.; Cavnar, M.J.; Cohen, N.A.; Sorenson, E.C.; Greer, J.B.; Seifert, A.M.; Crawley, M.H.; Green, B.L.; Popow, R.; Pillarsetty, N.; et al. Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor. Clin. Cancer Res. 2014, 20, 2350–2362. [CrossRef] [PubMed]
67. Patwardhan, P.P.; Surriga, O.; Beckman, M.J.; de Stanchina, E.; Dematteo, R.P.; Tap, W.D.; Schwartz, G.K. Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs. Clin. Cancer Res. 2014, 20, 3146–3158. [CrossRef] [PubMed]
68. Ries, C.H.; Cannarile, M.A.; Hoves, S.; Benz, J.; Wartha, K.; Runza, V.; Rey-Giraud, F.; Pradel, L.P.; Feuerhake, F.; Klaman, I.; et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 2014, 25, 846–859. [CrossRef] [PubMed]
69. Roche. Investor Update. Available online: http://www.roche.com/investors/updates/inv-update-2014-06-01.htm (accessed on 24 January 2017).
70. Duluc, D.; Corvaisier, M.; Blanchard, S.; Catala, L.; Descamps, P.; Gamelin, E.; Ponsoda, S.; Delneste, Y.; Hebbar, M.; Jeannin, P. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int. J. Cancer 2009, 125, 367–373. [CrossRef] [PubMed]
71. Tang, X.; Mo, C.; Wang, Y.; Wei, D.; Xiao, H. Anti-tumour strategies aiming to target tumour-associated macrophages. Immunology 2013, 138, 93–104. [CrossRef] [PubMed]
72. Beatty, G.L.; Chiorean, E.G.; Fishman, M.P.; Saboury, B.; Teitelbaum, U.R.; Sun, W.; Huhn, R.D.; Song, W.; Li, D.; Sharp, L.L., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331, 1612–1616. [CrossRef] [PubMed]
73. Buhtoiarov, I.N.; Lum, H.; Berke, G.; Paulnock, D.M.; Sondel, P.M.; Rakhmilevich, A.L. CD40 ligation activates murine macrophages via an IFN--dependent mechanism resulting in tumor cell destruction in vitro. J. Immunol. 2005, 174, 6013–6022. [CrossRef] [PubMed]
74. Buhtoiarov, I.N.; Lum, H.D.; Berke, G.; Sondel, P.M.; Rakhmilevich, A.L. Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. J. Immunol. 2006, 176, 309–318. [CrossRef] [PubMed]
75. Jensen, J.L.; Rakhmilevich, A.; Heninger, E.; Broman, A.T.; Hope, C.; Phan, F.; Miyamoto, S.; Maroulakou, I.; Callander, N.; Hematti, P.; Chesi, M., et al. Tumoricidal effects of macrophage-activating immunotherapy in a murine model of relapsed/refractory multiple myeloma. Cancer Immunol. Res. 2015, 3, 881–890. [CrossRef] [PubMed]
76. Mantovani, A.; Marchesi, F.; Malesci, A.; Laghi, L.; Allavena, P. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 2017. [CrossRef] [PubMed]
77. Olsson, A.; Nakhle, J.; Sundstedt, A.; Plas, P.; Bauchet, A.L.; Pierron, V.; Bruetschy, L.; Deronic, A.; Torngren, M.; Liberg, D., et al. Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment. J. Immunother. Cancer 2015, 3, 53. [CrossRef] [PubMed]
78. Shen, L.; Sundstedt, A.; Ciesielski, M.; Miles, K.M.; Celander, M.; Adelaiye, R.; Orillion, A.; Ciamporcero, E.; Ramakrishnan, S.; Ellis, L., et al. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunol. Res. 2015, 3, 136–148. [CrossRef] [PubMed]
79. White, E.S.; Flaherty, K.R.; Carskadon, S.; Brant, A.; Iannettoni, M.D.; Yee, J.; Orringer, M.B.; Arenberg, D.A. Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: Role in angiogenesis and prognosis. Clin. Cancer Res. 2003, 9, 853–860. [PubMed]
80. White, E.S.; Strom, S.R.; Wys, N.L.; Arenberg, D.A. Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity. J. Immunol. 2001, 166, 7549–7555. [CrossRef] [PubMed]
81. Yaddanapudi, K.; Putty, K.; Rendon, B.E.; Lamont, G.J.; Faughn, J.D.; Satoskar, A.; Lasnik, A.; Eaton, J.W.; Mitchell, R.A. Control of tumor-associated macrophage alternative activation by macrophage migration inhibitory factor. J. Immunol. 2013, 190, 2984–2993. [CrossRef] [PubMed]
82. Cheng, F.; Wang, H.W.; Cuenca, A.; Huang, M.; Ghansah, T.; Brayer, J.; Kerr, W.G.; Takeda, K.; Akira, S.; Schoenberger, S.P., et al. A critical role for Stat3 signaling in immune tolerance. Immunity 2003, 19, 425–436. [CrossRef]
83. Xin, H.; Zhang, C.; Herrmann, A.; Du, Y.; Figlin, R.; Yu, H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 2009, 69, 2506–2513. [CrossRef] [PubMed]
84. Edwards, J.P.; Emens, L.A. The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE(2) in murine macrophages. Int. Immunopharmacol. 2010, 10, 1220–1228. [CrossRef] [PubMed]
85. Hebenstreit, D.; Wirnsberger, G.; Horejs-Hoeck, J.; Duschl, A. Signaling mechanisms, interaction partners, and target genes of STAT 6. Cytokine Growth Factor Rev. 2006, 17, 173–188. [CrossRef] [PubMed]
86. Binnemars-Postma, K.; Bansal, R.; Storm, G.; Prakash, J. 355 Targeting the STAT6 pathway to inhibit tumor-associated macrophages-induced tumor growth and metastasis in breast cancer. Eur. J. Cancer 2015, 51, S72–S73. [CrossRef]
87. Germano, G.; Frapolli, R.; Belgiovine, C.; Anselmo, A.; Pesce, S.; Liguori, M.; Erba, E.; Uboldi, S.; Zucchetti, M.; Pasqualini, F., et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013, 23, 249–262. [CrossRef] [PubMed]
88. Rogers, T.L.; Holen, I. Tumour macrophages as potential targets of bisphosphonates. J. Transl. Med. 2011, 9, 177. [CrossRef] [PubMed]
89. Fleisch, H. Bisphosphonates: A new class of drugs in diseases of bone and calcium metabolism. Recent Results Cancer Res. 1989, 116, 1–28. [PubMed]
90. Van Rooijen, N.; van Nieuwmegen, R. Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. An enzyme-histochemical study. Cell Tissue Res. 1984, 238, 355–358. [CrossRef] [PubMed]
91. Brown, H.K.; Holen, I. Anti-tumour effects of bisphosphonates—What have we learned from in vivo models? Curr. Cancer Drug Targets 2009, 9, 807–823. [CrossRef] [PubMed]
92. Zeisberger, S.M.; Odermatt, B.; Marty, C.; Zehnder-Fjallman, A.H.; Ballmer-Hofer, K.; Schwendener, R.A. Clodronate-liposome-mediated depletion of tumour-associated macrophages: A new and highly effective antiangiogenic therapy approach. Br. J. Cancer 2006, 95, 272–281. [CrossRef] [PubMed]
93. Wu, X.; Schulte, B.C.; Zhou, Y.; Haribhai, D.; Mackinnon, A.C.; Plaza, J.A.; Williams, C.B.; Hwang, S.T. Depletion of M2-like tumor-associated macrophages delays cutaneous t-cell lymphoma development in vivo. J. Investig. Dermatol. 2014, 134, 2814–2822. [CrossRef] [PubMed]
94. Zhang, W.; Zhu, X.D.; Sun, H.C.; Xiong, Y.Q.; Zhuang, P.Y.; Xu, H.X.; Kong, L.Q.; Wang, L.; Wu, W.Z.; Tang, Z.Y. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin. Cancer Res. 2010, 16, 3420–3430. [CrossRef] [PubMed]
95. Junankar, S.; Shay, G.; Jurczyluk, J.; Ali, N.; Down, J.; Pocock, N.; Parker, A.; Nguyen, A.; Sun, S., et al. Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer. Cancer Discov. 2015, 5, 35–42. [CrossRef] [PubMed]
96. Guan, Y.; Sakai, R.; Rinehart, K.L.; Wang, A.H. Molecular and crystal structures of ecteinascidins: Potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata. J. Biomol. Struct. Dyn. 1993, 10, 793–818. [PubMed]
97. Allavena, P.; Signorelli, M.; Chieppa, M.; Erba, E.; Bianchi, G.; Marchesi, F.; Olimpio, C.O.; Bonardi, C.; Garbi, A.; Lissoni, A., et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): Inhibition of macrophage differentiation and cytokine production. Cancer Res. 2005, 65, 2964–2971. [CrossRef] [PubMed]
98. Pommier, Y.; Kohlhagen, G.; Bailly, C.; Waring, M.; Mazumder, A.; Kohn, K.W. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996, 35, 13303–13309. [CrossRef] [PubMed]
99. Zewail-Foote, M.; Hurley, L.H. Ecteinascidin 743: A minor groove alkylator that bends DNA toward the major groove. J. Med. Chem. 1999, 42, 2493–2497. [CrossRef] [PubMed]
100. Erba, E.; Bergamaschi, D.; Bassano, L.; Damia, G.; Ronzoni, S.; Faircloth, G.T.; D’Incalci, M. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur. J. Cancer 2001, 37, 97–105. [CrossRef]
101. D’Incalci, M.; Zambelli, A. Trabectedin for the treatment of breast cancer. Expert Opin. Investig. Drugs 2016, 25, 105–115. [CrossRef] [PubMed]
102. Germano, G.; Frapolli, R.; Simone, M.; Tavecchio, M.; Erba, E.; Pesce, S.; Pasqualini, F.; Grosso, F.; Sanfilippo, R.; Casali, P.G., et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 2010, 70, 2235–2244. [CrossRef] [PubMed]
103. Atmaca, H.; Uzunoglu, S. Anti-angiogenic effects of trabectedin (Yondelis; ET-743) on human breast cancer cells. Eur. Cytokine Netw. 2014, 25, 1–7. [PubMed]
104. Flannagan, R.S.; Jaumouille, V.; Grinstein, S. The cell biology of phagocytosis. Annu. Rev. Pathol. 2012, 7, 61–98. [CrossRef] [PubMed]
105. Alexis, F.; Pridgen, E.; Molnar, L.K.; Farokhzad, O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 2008, 5, 505–515. [CrossRef] [PubMed]
106. Haniffa, M.; Bigley, V.; Collin, M. Human mononuclear phagocyte system reunited. Semin. Cell Dev. Biol. 2015, 41, 59–69. [CrossRef] [PubMed]
107. Liu, T.; Choi, H.; Zhou, R.; Chen, I.W. Quantitative evaluation of the reticuloendothelial system function with dynamic MRI. PLoS ONE 2014, 9, e103576. [CrossRef] [PubMed]
108. Owens, D.E., 3rd; Peppas, N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307, 93–102. [CrossRef] [PubMed]
109. Maeda, H.; Nakamura, H.; Fang, J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev. 2013, 65, 71–79. [CrossRef] [PubMed]
110. Nichols, J.W.; Bae, Y.H. EPR: Evidence and fallacy. J. Control Release 2014, 190, 451–464. [CrossRef] [PubMed]
111. Shi, J.; Kantoff, P.W.; Wooster, R.; Farokhzad, O.C. Cancer nanomedicine: Progress, challenges and opportunities. Nat. Rev. Cancer 2017, 17, 20–37. [CrossRef] [PubMed]
112. Anchordoquy, T.J.; Barenholz, Y.; Boraschi, D.; Chorny, M.; Decuzzi, P.; Dobrovolskaia, M.A.; Farhangrazi, Z.S.; Farrell, D.; Gabizon, A.; Ghandehari, H., et al. Mechanisms and barriers in cancer nanomedicine: Addressing challenges, looking for solutions. ACS Nano 2017, 11, 12–18. [CrossRef] [PubMed]
113. Miller, M.A.; Gadde, S.; Pfirschke, C.; Engblom, C.; Sprachman, M.M.; Kohler, R.H.; Yang, K.S.; Laughney, A.M.; Wojtkiewicz, G.; Kamaly, N., et al. Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle. Sci. Transl. Med. 2015, 7, 314ra183. [CrossRef] [PubMed]
114. Miller, M.A.; Zheng, Y.R.; Gadde, S.; Pfirschke, C.; Zope, H.; Engblom, C.; Kohler, R.H.; Iwamoto, Y.; Yang, K.S.; Askevold, B., et al. Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug. Nat. Commun. 2015, 6, 8692. [CrossRef] [PubMed]
115. Si, J.; Shao, S.; Shen, Y.; Wang, K. Macrophages as active nanocarriers for targeted early and adjuvant cancer chemotherapy. Small 2016, 12, 5108–5119. [CrossRef] [PubMed]
116. Allen, T.M.; Cullis, P.R. Liposomal drug delivery systems: From concept to clinical applications. Adv. Drug Deliv. Rev. 2013, 65, 36–48. [CrossRef] [PubMed]
117. Shmeeda, H.; Amitay, Y.; Gorin, J.; Tzemach, D.; Mak, L.; Stern, S.T.; Barenholz, Y.; Gabizon, A. Coencapsulation of alendronate and doxorubicin in pegylated liposomes: A novel formulation for chemoimmunotherapy of cancer. J. Drug Target 2016, 24, 878–889. [CrossRef] [PubMed]
118. Qi, X.F.; Kim, D.H.; Yoon, Y.S.; Kim, S.K.; Cai, D.Q.; Teng, Y.C.; Shim, K.Y.; Lee, K.J. Involvement of oxidative stress in simvastatin-induced apoptosis of murine CT26 colon carcinoma cells. Toxicol. Lett. 2010, 199, 277–287. [CrossRef] [PubMed]
119. Alupei, M.C.; Licarete, E.; Patras, L.; Banciu, M. Liposomal simvastatin inhibits tumor growth via targeting tumor-associated macrophages-mediated oxidative stress. Cancer Lett. 2015, 356 Pt 2, 946–952. [CrossRef] [PubMed]
120. Perez-Herrero, E.; Fernandez-Medarde, A. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur. J. Pharm. Biopharm. 2015, 93, 52–79. [CrossRef] [PubMed]
121. Peres, C.; Matos, A.I.; Conniot, J.; Sainz, V.; Zupancic, E.; Silva, J.M.; Graca, L.; Sa Gaspar, R.; Preat, V.; Florindo, H.F. Poly(lactic acid)-based particulate systems are promising tools for immune modulation. Acta Biomater. 2017, 48, 41–57. [CrossRef] [PubMed]
122. Zou, L.; Tao, Y.; Payne, G.; Do, L.; Thomas, T.; Rodriguez, J.; Dou, H. Targeted delivery of nano-PTX to the brain tumor-associated macrophages. Oncotarget 2017, 8, 6564–6578. [CrossRef] [PubMed]
123. Ernsting, M.J.; Hoang, B.; Lohse, I.; Undzys, E.; Cao, P.; Do, T.; Gill, B.; Pintilie, M.; Hedley, D.; Li, S.D. Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle. J. Control Release 2015, 206, 122–130. [CrossRef] [PubMed]
124. Cerulean Pharma Inc. Platform & Pipeline CRLX101. Available online: http://ceruleanrx.com/platformpipeline/crlx101.php (accessed on 23 January 2017).
125. Alizadeh, D.; Zhang, L.; Hwang, J.; Schluep, T.; Badie, B. Tumor-associated macrophages are predominant carriers of cyclodextrin-based nanoparticles into gliomas. Nanomedicine 2010, 6, 382–390. [CrossRef] [PubMed]
126. Zhang, F.; Mastorakos, P.; Mishra, M.K.; Mangraviti, A.; Hwang, L.; Zhou, J.; Hanes, J.; Brem, H.; Olivi, A.; Tyler, B., et al. Uniform brain tumor distribution and tumor associated macrophage targeting of systemically administered dendrimers. Biomaterials 2015, 52, 507–516. [CrossRef] [PubMed]
127. Bashir, M.R.; Bhatti, L.; Marin, D.; Nelson, R.C. Emerging applications for ferumoxytol as a contrast agent in MRI. J. Magn. Reson. Imaging 2015, 41, 884–898. [CrossRef] [PubMed]
128. Zanganeh, S.; Hutter, G.; Spitler, R.; Lenkov, O.; Mahmoudi, M.; Shaw, A.; Pajarinen, J.S.; Nejadnik, H.; Goodman, S.; Moseley, M., et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat. Nanotechnol. 2016, 11, 986–994. [CrossRef] [PubMed]
129. Kruse, C.A.; Freehauf, C.L.; Patel, K.R.; Baldeschwieler, J.D. Mouse erythrocyte carriers osmotically loaded with methotrexate. Biotechnol. Appl. Biochem. 1987, 9, 123–140. [PubMed]
130. Rossi, L.; Serafini, S.; Antonelli, A.; Pierige, F.; Carnevali, A.; Battistelli, V.; Malatesta, M.; Balestra, E.; Calio, R.; Perno, C.F., et al. Macrophage depletion induced by clodronate-loaded erythrocytes. J. Drug Target 2005, 13, 99–111. [CrossRef] [PubMed]
131. Sabatino, R.; Antonelli, A.; Battistelli, S.; Schwendener, R.; Magnani, M.; Rossi, L. Macrophage depletion by free bisphosphonates and zoledronate-loaded red blood cells. PLoS ONE 2014, 9, e101260. [CrossRef] [PubMed]
132. Duivenvoorden, R.; Tang, J.; Cormode, D.P.; Mieszawska, A.J.; Izquierdo-Garcia, D.; Ozcan, C.; Otten, M.J.; Zaidi, N.; Lobatto, M.E.; van Rijs, S.M., et al. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat. Commun. 2014, 5, 3065. [PubMed]
133. Tang, J.; Lobatto, M.E.; Hassing, L.; van der Staay, S.; van Rijs, S.M.; Calcagno, C.; Braza, M.S.; Baxter, S.; Fay, F.; Sanchez-Gaytan, B.L., et al. Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation. Sci. Adv. 2015, 1, e1400223. [CrossRef] [PubMed]
134. Perez-Medina, C.; Tang, J.; Abdel-Atti, D.; Hogstad, B.; Merad, M.; Fisher, E.A.; Fayad, Z.A.; Lewis, J.S.; Mulder, W.J.; Reiner, T. PET imaging of tumor-associated macrophages with 89Zr-labeled high-density lipoprotein nanoparticles. J. Nucl. Med. 2015, 56, 1272–1277. [CrossRef] [PubMed]
135. Agrawal, A.; Manchester, M. Differential uptake of chemically modified cowpea mosaic virus nanoparticles in macrophage subpopulations present in inflammatory and tumor microenvironments. Biomacromolecules 2012, 13, 3320–3326. [CrossRef] [PubMed]
136. Wen, A.M.; Lee, K.L.; Cao, P.; Pangilinan, K.; Carpenter, B.L.; Lam, P.; Veliz, F.A.; Ghiladi, R.A.; Advincula, R.C.; Steinmetz, N.F. Utilizing viral nanoparticle/dendron hybrid conjugates in photodynamic therapy for dual delivery to macrophages and cancer cells. Bioconjug. Chem. 2016, 27, 1227–1235. [CrossRef] [PubMed]
137. Klumpp, C.; Kostarelos, K.; Prato, M.; Bianco, A. Functionalized carbon nanotubes as emerging nanovectors for the delivery of therapeutics. Biochim. Biophys. Acta 2006, 1758, 404–412. [CrossRef] [PubMed]
138. VanHandel, M.; Alizadeh, D.; Zhang, L.; Kateb, B.; Bronikowski, M.; Manohara, H.; Badie, B. Selective uptake of multi-walled carbon nanotubes by tumor macrophages in a murine glioma model. J. Neuroimmunol. 2009, 208, 3–9. [CrossRef] [PubMed]
139. Zhao, D.; Alizadeh, D.; Zhang, L.; Liu, W.; Farrukh, O.; Manuel, E.; Diamond, D.J.; Badie, B. Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity. Clin. Cancer Res. 2011, 17, 771–782. [CrossRef] [PubMed]
140. Fan, H.; Zhang, I.; Chen, X.; Zhang, L.; Wang, H.; Da Fonseca, A.; Manuel, E.R.; Diamond, D.J.; Raubitschek, A.; Badie, B. Intracerebral CpG immunotherapy with carbon nanotubes abrogates growth of subcutaneous melanomas in mice. Clin. Cancer Res. 2012, 18, 5628–5638. [CrossRef] [PubMed]
141. Lohcharoenkal, W.; Zhang, I.; Chen, X.; Zhang, L.; Wang, H.; Da Fonseca, A.; Manuel, E.R.; Diamond, D.J.; Raubitschek, A.; Badie, B. Protein nanoparticles as drug delivery carriers for cancer therapy. BioMed Res. Int. 2014, 2014, 180549. [CrossRef] [PubMed]
142. Kundranda, M.N.; Niu, J. Albumin-bound paclitaxel in solid tumors: Clinical development and future directions. Drug Des. Dev. Ther. 2015, 9, 3767–3777. [CrossRef] [PubMed]
143. Desai, N.; Trieu, V.; Yao, Z.; Louie, L.; Ci, S.; Yang, A.; Tao, C.; De, T.; Beals, B.; Dykes, D., et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 2006, 12, 1317–1324. [CrossRef] [PubMed]
144. Desai, N.P.; Trieu, V.; Hwang, L.Y.; Wu, R.; Soon-Shiong, P.; Gradishar, W.J. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008, 19, 899–909. [CrossRef] [PubMed]
145. Desai, N.; Trieu, V.; Damascelli, B.; Soon-Shiong, P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl. Oncol. 2009, 2, 59–64. [CrossRef] [PubMed]
146. Cullis, J.; Siolas, D.; Avanzi, A.; Barui, S.; Maitra, A.; Bar-Sagi, D. Macropinocytosis of nab-paclitaxel drives macrophage activation in pancreatic cancer. Cancer Immunol. Res. 2017, 5, 182–190. [CrossRef] [PubMed]
147. Tanei, T.; Leonard, F.; Liu, X.; Alexander, J.F.; Saito, Y.; Ferrari, M.; Godin, B.; Yokoi, K. Redirecting transport of nanoparticle albumin-bound paclitaxel to macrophages enhances therapeutic efficacy against liver metastases. Cancer Res. 2016, 76, 429–439. [CrossRef] [PubMed]
148. Verma, A.; Stellacci, F. Effect of surface properties on nanoparticle-cell interactions. Small 2010, 6, 12–21. [CrossRef] [PubMed]
149. Binnemars-Postma, K.A.; Ten Hoopen, H.W.; Storm, G.; Prakash, J. Differential uptake of nanoparticles by human M1 and M2 polarized macrophages: Protein corona as a critical determinant. Nanomedicine 2016, 11, 2889–2902. [CrossRef] [PubMed]
150. Perrie, Y.; Frederik, P.M.; Gregoriadis, G. Liposome-mediated DNA vaccination: The effect of vesicle composition. Vaccine 2001, 19, 3301–3310. [CrossRef]
151. Ishii, N.; Fukushima, J.; Kaneko, T.; Okada, E.; Tani, K.; Tanaka, S.I.; Hamajima, K.; Xin, K.Q.; Kawamoto, S.; Koff, W. et al. Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 1997, 13, 1421–1428. [CrossRef] [PubMed]
152. Tanaka, M.; Kaneda, Y.; Fujii, S.; Yamano, T.; Hashimoto, K.; Huang, S.K.; Hoon, D.S. Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma. Mol. Ther. 2002, 5, 291–299. [CrossRef] [PubMed]
153. Toda, S.; Ishii, N.; Okada, E.; Kusakabe, K.I.; Arai, H.; Hamajima, K.; Gorai, I.; Nishioka, K.; Okuda, K. HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-gamma antibody. Immunology 1997, 92, 111–117. [CrossRef] [PubMed]
154. Hattori, Y.; Kawakami, S.; Suzuki, S.; Yamashita, F.; Hashida, M. Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice. Biochem. Biophys. Res. Commun. 2004, 317, 992–999. [CrossRef] [PubMed]
155. Locke, L.W.; Mayo, M.W.; Yoo, A.D.; Williams, M.B.; Berr, S.S. PET imaging of tumor associated macrophages using mannose coated 64Cu liposomes. Biomaterials 2012, 33, 7785–7793. [CrossRef] [PubMed]
156. Kaur, A.; Jain, S.; Tiwary, A.K. Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: In vitro and in vivo evaluation. Acta Pharm. 2008, 58, 61–74. [CrossRef] [PubMed]
157. Yu, W.; Liu, C.; Liu, Y.; Zhang, N.; Xu, W. Mannan-modified solid lipid nanoparticles for targeted gene delivery to alveolar macrophages. Pharm. Res. 2010, 27, 1584–1596. [CrossRef] [PubMed]
158. Zhan, X.; Jia, L.; Niu, Y.; Qi, H.; Chen, X.; Zhang, Q.; Zhang, J.; Wang, Y.; Dong, L.; Wang, C. Targeted depletion of tumour-associated macrophages by an alendronate-glucomannan conjugate for cancer immunotherapy. Biomaterials 2014, 35, 10046–10057. [CrossRef] [PubMed]
159. Zhu, S.; Niu, M.; O’Mary, H.; Cui, Z. Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles. Mol. Pharm. 2013, 10, 3525–3530. [CrossRef] [PubMed]
160. Niu, M.; Naguib, Y.W.; Aldayel, A.M.; Shi, Y.C.; Hursting, S.D.; Hersh, M.A.; Cui, Z. Biodistribution and in vivo activities of tumor-associated macrophage-targeting nanoparticles incorporated with doxorubicin. Mol. Pharm. 2014, 11, 4425–4436. [CrossRef] [PubMed]
161. Niu, M.; Valdes, S.; Naguib, Y.W.; Hursting, S.D.; Cui, Z. Tumor-associated macrophage-mediated targeted therapy of triple-negative breast cancer. Mol. Pharm. 2016, 13, 1833–1842. [CrossRef] [PubMed]
162. Ortega, R.A.; Barham, W.J.; Kumar, B.; Tikhomirov, O.; McFadden, I.D.; Yull, F.E.; Giorgio, T.D. Biocompatible mannosylated endosomal-escape nanoparticles enhance selective delivery of short nucleotide sequences to tumor associated macrophages. Nanoscale 2014, 7, 500–510. [CrossRef] [PubMed]
163. Ortega, R.A.; Barham, W.; Sharman, K.; Tikhomirov, O.; Giorgio, T.D.; Yull, F.E. Manipulating the NF-κB pathway in macrophages using mannosylated, siRNA-delivering nanoparticles can induce immunostimulatory and tumor cytotoxic functions. Int. J. Nanomed. 2016, 11, 2163–2177. [CrossRef] [PubMed]
164. Yu, S.S.; Lau, C.M.; Barham, W.J.; Onishko, H.M.; Nelson, C.E.; Li, H.; Smith, C.A.; Yull, F.E.; Duvall, C.L.; Giorgio, T.D. Macrophage-specific RNA interference targeting via “click”, mannosylated polymeric micelles. Mol. Pharm. 2013, 10, 975–987. [CrossRef] [PubMed]
165. Turk, M.J.; Waters, D.J.; Low, P.S. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett. 2004, 213, 165–172. [CrossRef] [PubMed]
166. Puig-Kroger, A.; Sierra-Filardi, E.; Dominguez-Soto, A.; Samaniego, R.; Corcuera, M.T.; Gomez-Aguado, F.; Ratnam, M.; Sanchez-Mateos, P.; Corbi, A.L. Folate receptor β is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. Cancer Res. 2009, 69, 9395–9403. [CrossRef] [PubMed]
167. Nagai, T.; Tanaka, M.; Tsuneyoshi, Y.; Xu, B.; Michie, S.A.; Hasui, K.; Hirano, H.; Arita, K.; Matsuyama, T. Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor β. Cancer Immunol. Immunother. 2009, 58, 1577–1586. [CrossRef] [PubMed]
168. Hattori, Y.; Yamashita, J.; Sakaida, C.; Kawano, K.; Yonemochi, E. Evaluation of antitumor effect of zoledronic acid entrapped in folate-linked liposome for targeting to tumor-associated macrophages. J. Liposome Res. 2015, 25, 131–140. [CrossRef] [PubMed]
169. Daldrup-Link, H.E.; Golovko, D.; Ruffell, B.; Denardo, D.G.; Castaneda, R.; Ansari, C.; Rao, J.; Tikhomirov, G.A.; Wendland, M.F.; Corot, C. et al. MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin. Cancer Res. 2011, 17, 5695–5704. [CrossRef] [PubMed]
170. Tang, X. Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. Cancer Lett. 2013, 332, 3–10. [CrossRef] [PubMed]
171. Fabriek, B.O.; Dijkstra, C.D.; van den Berg, T.K. The macrophage scavenger receptor CD 163. Immunobiology 2005, 210, 153–160. [CrossRef] [PubMed]
172. Gordon, S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3, 23–35. [CrossRef] [PubMed]
173. Etzerodt, A.; Maniecki, M.B.; Graversen, J.H.; Moller, H.J.; Torchilin, V.P.; Moestrup, S.K. Efficient intracellular drug-targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD 163. J. Control Release 2012, 160, 72–80. [CrossRef] [PubMed]
174. Liu, C.; Sun, C.; Huang, H.; Janda, K.; Edgington, T. Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. 2003, 63, 2957–2964. [PubMed]
175. Murthy, R.V.; Arbman, G.; Gao, J.; Roodman, G.D.; Sun, X.F. Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. Clin. Cancer Res. 2005, 11, 2293–2299. [CrossRef] [PubMed]
176. Luo, Y.; Zhou, H.; Krueger, J.; Kaplan, C.; Lee, S.H.; Dolman, C.; Markowitz, D.; Wu, W.; Liu, C.; Reisfeld, R.A. et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J. Clin. Investig. 2006, 116, 2132–2141. [CrossRef] [PubMed]
177. Liao, D.; Liu, Z.; Wrasidlo, W.; Chen, T.; Luo, Y.; Xiang, R.; Reisfeld, R.A. Synthetic enzyme inhibitor: A novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity. Nanomedicine 2011, 7, 665–673. [CrossRef] [PubMed]
178. Zhang, X.; Tian, W.; Cai, X.; Wang, X.; Dang, W.; Tang, H.; Cao, H.; Wang, L.; Chen, T. Hydrazinocurcumin Encapsuled nanoparticles “re-educate” tumor-associated macrophages and exhibit anti-tumor effects on breast cancer following STAT3 suppression. PLoS ONE 2013, 8, e65896. [CrossRef] [PubMed]
179. Song, X.; Wan, Z.; Chen, T.; Fu, Y.; Jiang, K.; Yi, X.; Ke, H.; Dong, J.; Yang, L.; Li, L. et al. Development of a multi-target peptide for potentiating chemotherapy by modulating tumor microenvironment. Biomaterials 2016, 108, 44–56. [CrossRef] [PubMed]
180. Raes, G.; Brys, L.; Dahal, B.K.; Brandt, J.; Grooten, J.; Brombacher, F.; Vanham, G.; Noel, W.; Bogaert, P.; Boonefaes, T. et al. Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. J. Leukoc. Biol. 2005, 77, 321–327. [CrossRef] [PubMed]
181. Huang, Z.; Zhang, Z.; Jiang, Y.; Zhang, D.; Chen, J.; Dong, L.; Zhang, J. Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy. J. Control Release 2012, 158, 286–292. [CrossRef] [PubMed]
182. Zhang, M.; Kim, J.A. Effect of molecular size and modification pattern on the internalization of water soluble β-(1→3)-(1→4)-glucan by primary murine macrophages. Int. J. Biochem. Cell Biol. 2012, 44, 914–927. [CrossRef] [PubMed]
183. Zhang, M.; Gao, Y.; Caja, K.; Zhao, B.; Kim, J.A. Non-viral nanoparticle delivers small interfering RNA to macrophages in vitro and in vivo. PLoS ONE 2015, 10, e0118472. [CrossRef] [PubMed]
184. Cieslewicz, M.; Tang, J.; Yu, J.L.; Cao, H.; Zavaljevski, M.; Motoyama, K.; Lieber, A.; Raines, E.W.; Pun, S.H. Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival. Proc. Natl. Acad. Sci. USA 2013, 110, 15919–15924. [CrossRef] [PubMed]
185. Cook, J.; Hagemann, T. Tumour-associated macrophages and cancer. Curr. Opin. Pharmacol. 2013, 13, 595–601. [CrossRef] [PubMed]
186. Shmeeda, H.; Amitay, Y.; Tzemach, D.; Gorin, J.; Gabizon, A. Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity. J. Control Release 2013, 167, 265–275. [CrossRef] [PubMed]
187. Golbar, H.M.; Izawa, T.; Wijesundera, K.K.; Bondoc, A.; Tennakoon, A.H.; Kuwamura, M.; Yamate, J. Depletion of hepatic macrophages aggravates liver lesions induced in rats by thioacetamide (TAA). Toxicol. Pathol. 2016, 44, 246–258. [CrossRef] [PubMed]
188. Liu, X.; Liu, Y.; Zhao, L.; Zeng, Z.; Xiao, W.; Chen, P. Macrophage depletion impairs skeletal muscle regeneration: The roles of regulatory factors for muscle regeneration. Cell Biol. Int. 2017, 41, 228–238. [CrossRef] [PubMed]
189. Mosser, D.M.; Edwards, J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8, 958–969. [CrossRef] [PubMed]
190. Patel, S.K.; Janjic, J.M. Macrophage targeted theranostics as personalized nanomedicine strategies for inflammatory diseases. Theranostics 2015, 5, 150–172. [CrossRef] [PubMed]
191. Hoppstadter, J.; Seif, M.; Dembek, A.; Cavelius, C.; Huwer, H.; Kraegeloh, A.; Kiemer, A.K. M2 polarization enhances silica nanoparticle uptake by macrophages. Front. Pharmacol. 2015, 6, 55. [CrossRef] [PubMed]